RxDoctor Payments Data

Faez Ayoob, MD

Vascular Surgery · Phoenix, AZNPI 1447505458

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $10,381 of the $15,990 with a category attached, or 64.9%. 12 manufacturers reported payments, led by Boston Scientific at 30.8% of the total. Reporting peaked in 2023 at $7,798 and has fallen 62.4% since, to $2,933 in 2025.

$15,990in general payments, 2019–2025

Across 91 payments — averaging $175.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$5K
  • Penumbra, Inc.$4K
  • Medtronic$4K
  • W. L. Gore & Associates, Inc.$2K
  • Endologix LLC$1K
  • Surmodics, Inc.$85
  • plus $278 from 6 others
$625in research payments, 2019–2025

Across 1 payment — averaging $625.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Inspiremd Ltd$625

What the payments were for

  • Travel & lodging$10,38165%
  • Food & beverage$5,41734%
  • Education$1911%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,990 in reported general payments places this provider in the 70th percentile of 105 vascular surgery providers in Arizona.

See all vascular surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$54,695
Medicare patients
557
Services billed
868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cilostazol79$1,849
Rosuvastatin Calcium16$502
ClopidogrelClopidogrel Bisulfate66$366
Gabapentin16$149

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →